36 results about "Tumor Antibodies" patented technology

The present application describes antibodies that selectively bind human FcyRIIB, with little or no binding to other human FcgammaRs, e.g., human FcgammaRIIA. The invention also provides isolated bispecific antibodies comprising an antibody that selectively binds FcgammaRIIB, and a second antibody that specifically binds an activating receptor. Various uses, including therapeutic uses, for those antibodies are also described, including administration with anti-tumor antibodies and methods of inhibiting immune responses and suppressing histamine release.

The invention provides antibodies targeted at a tumor antigen prevalent on prostate tumors and methods useful in alleviating cancers expressing the antigen, as well as nucleic acids and cells for expressing the antibodies.

The present invention relates to compositions and methods that provide novel anti-tumor therapies in cancer. In one aspect, the present invention features a hybrid neutrophil in a non-naturally occurring container, wherein the hybrid neutrophil expresses at least one neutrophil associated molecule selected from the group consisting of: Arg1, MPO, CD66b, and CD15, and at least one antigen-presenting cell (APC) associated molecule selected from the group consisting of: CD14, HLA-DR, CD32, CD64, and CD89. In another aspect, the present invention features methods of generating a hybrid neutrophil. In still another aspect, the present invention features methods of inhibiting tumor growth in a subject, treating a tumor in a subject, and increasing efficacy of an antibody against a tumor in a subject. The methods comprise (a) administering to the subject an effective amount of an anti-tumor antibody and (b) administering to or generating in the subject an effective amount of a hybrid neutrophil.

The invention discloses a compound antibody containing interferon alpha/tumor antibody/oxidized graphene as well as a preparation method and applications. The compound antibody contains interferon alpha, the tumor antibody and oxidized graphene, wherein the interferon alpha, the tumor antibody and oxidized graphene are connected through non covalent bonds, and the tumor antibody is rituximab or trastuzumab. The compound antibody containing interferon alpha/tumor antibody/oxidized graphene can effectively and directly kill most tumor cells and damage the microenvironment protecting the tumor cells, and meanwhile, the interferon alpha stimulates an immune system, breaks the tumor tolerance, and promotes the specific cellular activation of tumors or the release of cell factors, so that the purposes of shrinking or eliminating tumors, preventing relapse and finally completely treating tumors are achieved.

The invention relates to a multi-signal embedded antigen receptor and an expression gene thereof, an NK (Natural Killer) cell modified by the multi-signal embedded antigen receptor and application. The embedded antigen receptor comprises a first segment, a second segment and a self-pyrolysis polypeptide T2A for connecting the first segment and the second segment, wherein the first segment comprises a first signal peptide, a TCRgamma chain and a TCRdelta chain, which are connected in sequence; the second segment comprises a second signal peptide SP, a tumor antibody, a CD8 structure domain, a 41BB intracellular domain and a DAP12-ITAM structural domain, which are connected in sequence; a C end of the self-pyrolysis polypeptide T2A is connected with the TCRdelta chain; an N end of the self-pyrolysis polypeptide T2A is connected with the second signal peptide SP. An experiment result shows that the multi-signal embedded antigen receptor can be stably expressed in the NK cell and can be used for more rapidly and specifically identifying malignant tumor cells and killing the malignant tumor cells, and the toxic side effect of treatment is reduced.

A bispecific antibody that simultaneously targets humanized p185 and VEGF, consisting of the four peptide chains: two identical antibody light chains that are the light chains of the antibody that identify the epitope or antigen of p185, and two identical antibody heavy chains that have the amino acid sequence of a recombinant antibody from N- to C-terminus, a light chain sequence of the antibody that recognizes the p185 epitope or the antigen; a constant heavy chain region; a flexible short peptide sequence; and either a single-stranded variable region sequence (ScFv) of anti-VEGF antibody which recognizes the VEGF epitope or antigen, or a receptor domain sequence that binds to VEGF. The bispecific antibody has the ability to bind p185 and VEGF at the same time, inhibits the proliferation of tumor cells, and promotes the expression of IFN-γ by T lymphocytes; it may be applied as anti-tumor antibody drug.

The invention is applicable to the technical field of biological genes, and provides a nanobody, an encoding gene thereof, an expression vector, a host cell and application of the nanobody. The nanobody is a nanobody aiming at a Siglec-15 extracellular specific region, and comprises a nanobody as shown in at least one of amino acid sequences SEQ ID NO.8, SEQ ID NO.13, SEQ ID NO.18 and SEQ ID NO.23. According to the invention, the nanobody that can be specifically bound with the extracellular region of Siglec-15 is obtained for Siglec-15, and the nanobody has huge potential in research and development of Siglec-15 therapeutic antibodies, preferably anti-tumor antibody therapy. The nanobody has strong and fast tissue penetrating capacity, and can enter compact solid tumor tissue to play a role; and the molecular structure of the nanobody is relatively simple, fermentation production can be performed through an escherichia coli or yeast expression system, and the production cost is greatly reduced.

The invention discloses a pharmaceutical composition for synergistically enhancing an anti-HER2 positive tumor effect. The invention provides an anti-tumor composition. The anti-tumor composition is composed of an anti-HER2 humanized antibody and meclofenamic acid. The old drug of meclofenamic acid and the humanized anti-tumor antibody drug are combined for use according to a certain proportion, so that the dosage of each drug can be greatly reduced, the toxic and side effects can be reduced, the drug effect can be remarkably enhanced, and the drug resistance of tumor cells can be overcome. The synergistic drug combined cocktail drug therapy has a wide prospect in tumor treatment.

The invention discloses a lead compound of a tumor treatment electric field, a preparation method of the lead compound and a sensitization tumor treatment electric field, the lead compound comprises atumor antibody, graphene oxide and ferroferric oxide, and the tumor antibody, the graphene oxide and the ferroferric oxide are connected through non-covalent bonds; and the tumor antibody is a cetuximab. According to the lead compound of the tumor treatment electric field, the tumor antibody, graphene oxide and ferroferric oxide are connected through non-covalent bonds to form the lead compound of the tumor treatment electric field. The glioma cell mitosis is effectively blocked in a medium-frequency low-intensity electric field, glioma cell proliferation is inhibited, glioma cell death is promoted, and glioma cells are killed. The formed lead compound effectively and directly kills most of tumor cells, and can greatly enhance the biological reaction. Moreover, the lead compound of the tumor treatment electric field can sensitize the electric field, reduce the adverse reaction of scalp and improve the safety and effectiveness of killing glioma cells.

The invention relates to a composite tumor antibody vaccine using a bacterial nano-magnetosome as a carrier, and a preparation method thereof. The composite tumor antibody vaccine is established withthe bacterial nano-magnetosome as the carrier, a novel simple and efficient antibody treatment mode is established, and a new immunization method is provided for biotherapy.